Figure 2From: Hereditary Angioedema Therapy: Kallikrein Inhibition and Bradykinin Receptor AntagonismThe randomized, double-blind, placebo-controlled EDEMA4 study demonstrated a statistically significant improvement in the Mean Symptom Complex Score (MSCS) at 4 hours after treatment with ecallantide compared with placebo for acute HAE episodes. Source: Developed from data provided in Table 7 of US Food and Drug Administration (www.fda.gov/ohrms/dockets/AC/09/briefing/20094413b1-03-Dyax.pdf).Back to article page